Large-scale randomised controlled trials in Europe and the United States are informing evidence-based clinical advice
Population-wide prostate-specific antigen (PSA) screening for prostate cancer is not recommended in Australia, primarily because of the lack of large-scale randomised trial evidence of a beneficial effect on prostate cancer mortality and the known harms of overdiagnosis and unnecessary treatment that may ensue. In spite of this, PSA testing is common; the limited evidence available suggests that more than 50% of Australian men over the age of 50 years have had the test.1,2
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.